Ultragenyx Pharmaceutical Inc.
RARE
$21.34
-$0.37-1.70%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 29.60% | -3.94% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 29.60% | -3.94% | |||
| Cost of Revenue | -4.74% | 30.08% | |||
| Gross Profit | 69.92% | -296.71% | |||
| SG&A Expenses | 1.52% | -0.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.10% | 20.57% | |||
| Operating Income | 33.71% | -58.40% | |||
| Income Before Tax | 28.88% | -57.49% | |||
| Income Tax Expenses | -0.34% | -7.81% | |||
| Earnings from Continuing Operations | 28.74% | -56.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 28.74% | -56.95% | |||
| EBIT | 33.71% | -58.40% | |||
| EBITDA | 35.61% | -63.48% | |||
| EPS Basic | 28.84% | -54.89% | |||
| Normalized Basic EPS | 29.52% | -56.01% | |||
| EPS Diluted | 28.84% | -54.89% | |||
| Normalized Diluted EPS | 29.52% | -56.01% | |||
| Average Basic Shares Outstanding | 0.13% | 1.33% | |||
| Average Diluted Shares Outstanding | 0.13% | 1.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||